Why BreastDefense?

BreastDefense answers a very simple but fundamental question. Is this tumor an indolent lesion, or an invasive breast cancer? This is a question that no other test can reliably answer. For breast cancer, the most common screening method - mammography - can be inaccurate. The New England Journal of Medicine estimates 31% of all breast cancer cases may be misdiagnosed.

BreastDefense does not rely on images, it is a lab developed molecular test.

Thousands of women are being misdiagnosed.

This needs to change.

With a simple blood draw, BreastDefense aims to distinguish benign and malignant tissue with a test that balances 98.5% accuracy for both sensitivity and specificity.

The Harm of Over-Diagnosis

What many women don't realize is the potential harm of over diagnosis, not to be confused with false positives. It is when a mammogram detects non-invasive or benign cancer which is unlikely to cause a problem. Currently, there is no way to tell, which can lead to unnecessary treatment.  

There is a clear path for commercializing BreastDefense

Step 1 The Validation Study Tissue Based – Timeline – 6-12 months.
Step 2 From the Validation Study a tissue-based test is ready for sale.
Step 3 Place BreastDefense in Blood Based Test (liquid biopsy) Timeline -12 months.
Step 4 BreastDefense Blood Based Screen is launched globally.